For example, with regard to Parkinson’s disease (PD), a dilemma arises when considering Grx1 as a PD-therapeutic target, namely whether to stimulate its upregulation for neuroprotection or to inhibit its proinflammatory activity [75]. The gene discussed is GLRX; the disease is Parkinson disease.